Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akero, Anavex, Biondvax, Biontech, Context, Corcept, Daiichi, Durect, Eyenovia, Ipsen, Matinas, Oncolys, Pfizer, Polypid, Revance, Timber, Vasopharm.

Zynerba Pharmaceuticals Inc.’s stock was slashed nearly in half June 30 as the company’s pivotal Connect-FX study for treating fragile X syndrome behavioral symptoms failed to achieve statistical significance in its primary and three key secondary endpoints.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alnylam, Altimmune, Amniox, Aobiome, Beyondspring, Blueprint, Can-Fite, Depuy, Exelixis, Galectin, Genmab, Humanigen, Impel, Inovio, Iveric, Marinus, Meissa, Nordic Nanovector, Novartis, Noxxon, Oncternal, Orexo, Orthocell, Reneuron, Revance, Rheacell, Roche, Rubius, Seattle Genetics, Zynerba.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 9 Meters, Achieve, Aileron, Biocardia, Cytodyn, Immutep, Immunovant, Intra-Cellular, Iterum, Kiniksa, KPB, Medicure, Revimmune, TFF, Tonix.

Shares of Kiniksa Pharmaceuticals Ltd. hit a 52-week high on June 29 as pivotal phase III results showed that Arcalyst (rilonacept), a medicine it licensed from Regeneron Pharmaceuticals Inc., led to a 96% reduction in risk of recurrent pericarditis events among 61 people not helped by standard-of-care treatments.

BEIJING – China this week approved both the country’s first mRNA vaccine candidate and its first recombinant protein subunit vaccine to begin clinical trials to fight COVID-19.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Highlight, Janssen, Onconano.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 9 Meters, Acceleron, Adial, Aiviva, Algernon, Assembly, Astrazeneca, Bergenbio, Geneuro, Insmed, Kiadis, Moberg, Neoimmunetech, Novan, Noxopharm, Oncolytics, Theravance.